These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20653107)

  • 1. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine.
    Zollinger WD; Donets MA; Schmiel DH; Pinto VB; Labrie JE; Moran EE; Brandt BL; Ionin B; Marques R; Wu M; Chen P; Stoddard MB; Keiser PB
    Vaccine; 2010 Jul; 28(31):5057-67. PubMed ID: 20653107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
    Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
    Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
    Keiser PB; Gibbs BT; Coster TS; Moran EE; Stoddard MB; Labrie JE; Schmiel DH; Pinto V; Chen P; Zollinger WD
    Vaccine; 2010 Oct; 28(43):6970-6. PubMed ID: 20732470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.
    Pinto VB; Moran EE; Cruz F; Wang XM; Fridman A; Zollinger WD; Przysiecki CT; Burden R
    Vaccine; 2011 Oct; 29(44):7752-8. PubMed ID: 21827811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
    Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
    Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.
    Pinto VB; Burden R; Wagner A; Moran EE; Lee CH
    PLoS One; 2013; 8(11):e79304. PubMed ID: 24244473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification.
    Zhang L; Wen Z; Lin J; Xu H; Herbert P; Wang XM; Mehl JT; Ahl PL; Dieter L; Russell R; Kosinski MJ; Przysiecki CT
    Vaccine; 2016 Jul; 34(35):4250-4256. PubMed ID: 27269057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
    Koeberling O; Ispasanie E; Hauser J; Rossi O; Pluschke G; Caugant DA; Saul A; MacLennan CA
    Vaccine; 2014 May; 32(23):2688-95. PubMed ID: 24704334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.
    Beernink PT; Ispasanie E; Lewis LA; Ram S; Moe GR; Granoff DM
    J Infect Dis; 2019 Mar; 219(7):1130-1137. PubMed ID: 30346576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
    Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
    Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.
    Fisseha M; Chen P; Brandt B; Kijek T; Moran E; Zollinger W
    Infect Immun; 2005 Jul; 73(7):4070-80. PubMed ID: 15972495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
    Marsay L; Dold C; Green CA; Rollier CS; Norheim G; Sadarangani M; Shanyinde M; Brehony C; Thompson AJ; Sanders H; Chan H; Haworth K; Derrick JP; Feavers IM; Maiden MC; Pollard AJ
    J Infect; 2015 Sep; 71(3):326-37. PubMed ID: 25982025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of vaccine potential of the Neisseria-specific protein NMB0938.
    Sardiñas G; Climent Y; Rodríguez Y; González S; García D; Cobas K; Caballero E; Pérez Y; Brookes C; Taylor S; Gorringe A; Delgado M; Pajón R; Yero D
    Vaccine; 2009 Nov; 27(49):6910-7. PubMed ID: 19751688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.
    Koeberling O; Delany I; Granoff DM
    Clin Vaccine Immunol; 2011 May; 18(5):736-42. PubMed ID: 21367981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J
    Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.